IgG4 (EP138) Rabbit Monoclonal Antibody
Specialties: Gastrointestinal (GI) Pathology Anatomic Pathology
IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. Clinical manifestations are apparent in the pancreas, bile duct, gall bladder, lacrimal gland, salivary gland, retroperitoneum, kidney, lung, breast, thyroid, and prostate. Immunohistochemical analyses in the case of IgG4-related sclerosing disease not only exhibit significantly more than normal IgG4-positive plasma cells in affected tissues but also significantly higher IgG4/IgG ratios (typically > 30%).1-8
- Sakata N, et al. IgG4-positive plasma cells in inflammatory abdominal aortic aneurysm: the possibility of an aortic manifestation of IgG4-related sclerosing disease. Am J Surg Pathol. 2008; 32:553-9.
- Dhobale S, et al. IgG4 related sclerosing disease with multiple organ involvements and response to corticosteroid treatment. J Clin Rheumatol. 2009; 15:354-7.
- Li Y, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto’s autoimmune thyroiditis. Pathol Int. 2009; 59:636-41.
- Cheuk W, et al. IgG4-related sclerosing mastitis: description of a new member of the IgG4-related sclerosing diseases. Am J Surg Pathol. 2009; 33:1058-64.
- Deshpande V, et al. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol. 2009; 22:1287-95.
- Sato Y, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease. Mod Pathol. 2009; 22: 589-99.
- Koyabu M et al. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol. 2010; 45:732-41.
- Kamisawa T, et al. Sclerosing cholangitis associated with autoimmune pancreatitis differs from primary sclerosing cholangitis. World J Gastroenterol. 2009; 21:2357-60.
Specifications
- Reactivity: paraffin
- Visualization: cytoplasmic
- Control: tonsil
- Dilution Range: 1:100-1:500*
Package Inserts
IFU
- IVD Rev. 2.0 (CMC36731020)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 367R-14 |
| 0.5 mL concentrate | 367R-15 |
| 1 mL concentrate | 367R-16 |
| 1 mL predilute | 367R-17 |
| 7 mL predilute | 367R-18 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 367R-14 |
| 0.5 mL concentrate | 367R-15 |
| 1 mL concentrate | 367R-16 |
| 1 mL predilute | 367R-17 |
| 7 mL predilute | 367R-18 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 367R-14 |
| 0.5 mL concentrate | 367R-15 |
| 1 mL concentrate | 367R-16 |
| 1 mL predilute | 367R-17 |
| 7 mL predilute | 367R-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate | 367R-14-RUO |
| 0.5 mL concentrate | 367R-15-RUO |
| 1 mL concentrate | 367R-16-RUO |
| 1 mL predilute | 367R-17-RUO |
| 7 mL predilute | 367R-18-RUO |
To request information on this product in additional countries, please click the button below.